NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8 ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, diseaseactivated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous' precision encrypted RNA™ (encRNA) techno ...

Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual Meeting Phase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at Upcoming Medical Conference Phase 1 Study in GvHD on Track for Activation in 2Q 2024 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invaria ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:3 ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:3 ...

On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed. Investor Contact Media Contact NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinicalstage biopharmaceutical company pioneering the discovery, development, and commercial ...

Group 1 - MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook for the stock due to rising earnings estimates [1][4][9] - The Zacks rating system is beneficial for investors as it reflects changes in earnings estimates, which are crucial for stock price movements [2][5] - The upgrade positions MiNK Therapeutics in the top 5% of Zacks-covered stocks, suggesting potential for near-term stock price increases [7][14] Group 2 - Over the past three months, the Zacks Consensus Estimate for MiNK Therapeutics has increased by 29.7%, indicating a significant upward revision in earnings expectations [12] - The company is projected to earn -$0.42 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 35.4% [13] - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988, highlighting the potential for market-beating returns [11]

Core Viewpoint - MiNK Therapeutics, Inc. is set to hold its Annual Shareholders Meeting virtually on June 12, 2024, focusing on its innovative iNKT cell therapies for cancer and immune-mediated diseases [1][4]. Group 1: Meeting Details - The Annual Shareholders Meeting will commence at 9:30 a.m. ET on June 12, 2024, with registration starting at 9:15 a.m. ET [1]. - Shareholders can participate by visiting a specific website and entering a control number, while guests can listen without a control number [2]. - A live webcast and replay of the meeting will be available on the company's website [3]. Group 2: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on the development of allogeneic invariant natural killer T (iNKT) cell therapies [4]. - The company is advancing a pipeline of both native and engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [4]. - MiNK Therapeutics is headquartered in New York, NY, and provides regular updates for investors through its website and social media [4].

Core Insights - MiNK Therapeutics, Inc. announced clinical data on agenT-797 for treating severe acute respiratory distress syndrome (ARDS) at the American Thoracic Society Annual Meeting, highlighting its potential in addressing critical unmet needs in immune-compromised patients [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, with a scalable manufacturing platform for off-the-shelf delivery [5]. Clinical Findings - A 26-year-old patient with chronic immunosuppression post-renal transplant contracted COVID-19 and developed severe hypoxemic respiratory failure, treated with a single dose of 1x10^9 allogeneic iNKT cells (agenT-797) [8]. - Following treatment, there was a rapid decrease in inflammatory cytokines, and the patient was extubated on day 37, discharged on day 60, and returned to normal activities within 6 months [8].